Recent advances in the medical therapy of Crohn's disease in childhood

被引:5
作者
Bremner, A. R.
Beattie, R. M.
机构
[1] Southampton Gen Hosp, Paediat Med Unit, Southampton SO16 6YD, Hants, England
[2] Bristol Royal Hosp Children, Dept Paediat Gastroenterol, Bristol BS2 8BJ, Avon, England
关键词
biological therapy; child; corticosteroid; Crohn's disease; enteral nutrition; immunosuppression; inflammatory bowel disease; probiotics; therapy;
D O I
10.1517/14656566.8.15.2553
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, including enteral nutrition, corticosteroids, immunosuppression and anti-TNF-alpha therapies. Anti-inf lammatory IL-11 and leukocyte adhesion inhibitors have shown only moderate clinical efficacy in adults. Emerging treatments directed against the inflammatory cascade under investigation include inhibitors of IL-6 and -12, IFN-gamma and MAPKs. Probiotics and colony stimulating factors aim to stimulate the innate immune system. Research data from clinical trials are reviewed and summarised in respect of their potential within paecliatric practice.
引用
收藏
页码:2553 / 2568
页数:16
相关论文
共 133 条
[1]   Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved [J].
Afzal, NA ;
Davies, S ;
Paintin, M ;
Arnaud-Battandier, F ;
Walker-Smith, JA ;
Murch, S ;
Heuschkel, R ;
Fell, J .
DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (08) :1471-1475
[2]  
Akobeng A K, 2004, Cochrane Database Syst Rev, pCD003574
[3]   Adult height in patients with early onset of Crohn's disease [J].
Alemzadeh, N ;
Rekers-Mombarg, LTM ;
Mearin, ML ;
Wit, JM ;
Lamers, CBHW ;
van Hogezand, RA .
GUT, 2002, 51 (01) :26-29
[4]   Methotrexate for induction of remission in refractory Crohn's disease [J].
Alfadhli, AAF ;
McDonald, JWD ;
Feagan, BG .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[5]   Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease [J].
Baldassano, R ;
Braegger, CP ;
Escher, JC ;
DeWoody, K ;
Hendricks, DF ;
Keenan, GF ;
Winter, HS .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (04) :833-838
[6]   Growth failure and intestinal inflammation [J].
Ballinger, AB ;
Camacho-Hübner, C ;
Croft, NM .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2001, 94 (03) :121-125
[7]   Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease [J].
Bauditz, J ;
Wedel, S ;
Lochs, H .
GUT, 2002, 50 (02) :196-200
[8]   Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease [J].
Baumgart, DC ;
Wiedenmann, B ;
Dignass, AU .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (10) :1273-1281
[9]   Inflammatory bowel disease [J].
Beattie, RM ;
Croft, NM ;
Fell, JM ;
Afzal, NA ;
Heuschkel, RB .
ARCHIVES OF DISEASE IN CHILDHOOD, 2006, 91 (05) :426-432
[10]   Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease [J].
Belluzzi, A ;
Brignola, C ;
Campieri, M ;
Pera, A ;
Boschi, S ;
Miglioli, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (24) :1557-1560